Stock SABS SAB BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Delayed Nasdaq
Other stock markets
 21:30:00 21/05/2024 BST 		5-day change 1st Jan Change
2.91 USD -15.65% Intraday chart for SAB Biotherapeutics, Inc. -28.06% -57.67%
05-20 SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
AQ
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
AQ
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
AQ
SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors
CI
SAB Biotherapeutics Provides SAB-142 Trial Update
AQ
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update
CI
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K
PU
SAB Biotherapeutics to Present at INNODIA Annual Meeting
AQ
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
AQ
HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating
MT
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
AQ
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K
PU
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
AQ
SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline
MT
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
AQ
Sab Biotherapeutics, Inc. Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
CI
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference
AQ
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SABS Stock
  4. News SAB Biotherapeutics, Inc.